Cargando…

Plasmapheresis as a viable treatment option for scleritis

PURPOSE: We describe a case and our experience with using plasmapheresis as a treatment for scleritis. OBSERVATIONS: Treating relapsing autoimmune scleritis can be challenging when it inadequately responds to traditional therapy. Our patient could not receive non-steroidal anti-inflammatory therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Preble, Janine M., Lin, Xihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243044/
https://www.ncbi.nlm.nih.gov/pubmed/35782168
http://dx.doi.org/10.1016/j.ajoc.2022.101627
_version_ 1784738215153893376
author Preble, Janine M.
Lin, Xihui
author_facet Preble, Janine M.
Lin, Xihui
author_sort Preble, Janine M.
collection PubMed
description PURPOSE: We describe a case and our experience with using plasmapheresis as a treatment for scleritis. OBSERVATIONS: Treating relapsing autoimmune scleritis can be challenging when it inadequately responds to traditional therapy. Our patient could not receive non-steroidal anti-inflammatory therapy for her scleritis due to recent gastrointestinal surgery and previously failed multiple steroid sparing treatments due to intolerance. There was good initial control with high dose oral prednisone, however, the steroid could not be tapered to a safe dosage (<10 mg per day) without relapse. Therefore, we opted to treat our patient with plasmapheresis. CONCLUSIONS AND IMPORTANCE: After undergoing plasmapheresis, our patient experienced total resolution of symptoms with corresponding clinical resolution of scleritis. Plasmapheresis derives great benefit by filtering circulating immune complexes. Although rarely used, plasmapheresis can be effective in treating non-infectious scleritis.
format Online
Article
Text
id pubmed-9243044
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92430442022-07-01 Plasmapheresis as a viable treatment option for scleritis Preble, Janine M. Lin, Xihui Am J Ophthalmol Case Rep Case Report PURPOSE: We describe a case and our experience with using plasmapheresis as a treatment for scleritis. OBSERVATIONS: Treating relapsing autoimmune scleritis can be challenging when it inadequately responds to traditional therapy. Our patient could not receive non-steroidal anti-inflammatory therapy for her scleritis due to recent gastrointestinal surgery and previously failed multiple steroid sparing treatments due to intolerance. There was good initial control with high dose oral prednisone, however, the steroid could not be tapered to a safe dosage (<10 mg per day) without relapse. Therefore, we opted to treat our patient with plasmapheresis. CONCLUSIONS AND IMPORTANCE: After undergoing plasmapheresis, our patient experienced total resolution of symptoms with corresponding clinical resolution of scleritis. Plasmapheresis derives great benefit by filtering circulating immune complexes. Although rarely used, plasmapheresis can be effective in treating non-infectious scleritis. Elsevier 2022-06-16 /pmc/articles/PMC9243044/ /pubmed/35782168 http://dx.doi.org/10.1016/j.ajoc.2022.101627 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Preble, Janine M.
Lin, Xihui
Plasmapheresis as a viable treatment option for scleritis
title Plasmapheresis as a viable treatment option for scleritis
title_full Plasmapheresis as a viable treatment option for scleritis
title_fullStr Plasmapheresis as a viable treatment option for scleritis
title_full_unstemmed Plasmapheresis as a viable treatment option for scleritis
title_short Plasmapheresis as a viable treatment option for scleritis
title_sort plasmapheresis as a viable treatment option for scleritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243044/
https://www.ncbi.nlm.nih.gov/pubmed/35782168
http://dx.doi.org/10.1016/j.ajoc.2022.101627
work_keys_str_mv AT preblejaninem plasmapheresisasaviabletreatmentoptionforscleritis
AT linxihui plasmapheresisasaviabletreatmentoptionforscleritis